DOCSLIB.ORG

Verapamil 40Mg, 80Mg, 120Mg and 160Mg Tablets

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

6 Contents of the pack and other information What Verapamil tablets contain • The active substance is verapamil hydrochloride. Package leaflet: Information for the patient Each tablet contains either 40mg, 80mg, 120mg or 160mg of verapamil hydrochloride. • The other ingredients are croscarmellose Verapamil 40mg, 80mg, 120mg sodium, magnesium stearate, maize starch, and 160mg tablets propylene glycol, sunset yellow aluminium lake (E110), quinoline yellow aluminium lake Read all of this leaflet carefully before you • manage high blood pressure (hypertension), (E104), titanium dioxide (E171), microcrystalline start taking this medicine because it contains used alone or with other drugs for high blood cellulose (E460), hydroxypropylcellulose (E463), pressure. methylhydroxypropylcellulose (E464), purified talc important information for you. • manage and prevent angina. (E553). • Keep this leaflet. You may need to read it again. • treat and prevent certain types of abnormal heartbeats. What Verapamil tablets look like and contents of • If you have any further questions, ask your the pack doctor or pharmacist. 2 What you need to know before you Verapamil 40mg tablets are yellow, circular, biconvex, • This medicine has been prescribed for you film-coated tablets, impressed “C” on one face and only. Do not pass it on to others. It may harm take Verapamil tablets Do not take Verapamil tablets if you: the identifying letters “VR” on the reverse. Tablet them, even if their signs of illness are the • are allergic to verapamil hydrochloride or any of diameter: 6.18-6.82mm. same as yours. the other ingredients of this medicine (listed in Verapamil 80mg tablets are yellow, circular, biconvex • If you get any side effects, talk to your doctor film-coated tablets, impressed “C” on one face and section 6) or pharmacist. This includes any possible side the identifying letters “VS” on the reverse. Tablet • have heart failure or severe problems with the effects not listed in this leaflet. See section 4. diameter: 7.6-8.4mm. impulses and rhythms of the heart (second or Verapamil 120mg tablets are yellow, circular, biconvex third degree atrioventricular block or sick film-coated tablets, impressed “C” on one face and What is in this leaflet sinus syndrome) unless you have a pacemaker the identifying letters “VT” on the reverse. Tablet 1 What Verapamil tablets are and what • have heart failure and are taking beta blockers diameter: 8.55-9.45mm. they are used for • have recently suffered a heart attack • suffer from a slow heart rate (bradycardia) Verapamil 160mg tablets are yellow, circular, biconvex 2 What you need to know before you • have low blood pressure (hypotension) film-coated tablets, impressed “C” on one face and take Verapamil tablets the identifying letters “VU” on the reverse. Tablet • have Wolff-Parkinson-White syndrome (rapid 3 How to take Verapamil tablets diameter: 9.98-11.02mm. heart rate sometimes associated with dizziness 4 Possible side effects or faintness) Pack sizes are 28, 56 and 84. 5 How to store Verapamil tablets • are already taking a medicine containing 6 Contents of the pack and other ivabradine for the treatment of certain heart Marketing Authorisation Holder and information diseases. Manufacturer Warnings and precautions Accord, Barnstaple, EX32 8NS, UK. 1 What Verapamil tablets are and what Talk to your doctor or pharmacist before taking they are used for Verapamil tablets if you have: This leaflet was last revised in December 2020 Verapamil belongs to a group of medicines called • had a heart attack or have problems with calcium-channel blockers which interfere with the the impulses of the heart (first degree electrical signals in the heart muscle and blood atrioventricular block) vessels. It is used to: • liver disease • kidney failure. 50995430 BBBA9696 Continued top of next column Continued over page 350x210 Leaflet Reel Fed Profile Landscape (BST) page 4 page 1 Verapamil BP Tablets Verapamil All Strengths 28, 56, 84 Tablets PIL - UK 40, 80, 120, 160mg x 25, 56, 84 (UK) approved for print/date Item number: BBBA9696 Colours Non Printing Colours JDE No.: 50995430 1. Black 1. Profile Originator: M.Doak Dimensions: 350 x 210mm 2. 2. Dimensions: 350x210 (Reel Fed) Origination Date: 17/11/2020 Min Body Text Size: 9 pt Component: Leaflet for Blisters Revision Date: 23/12/2020 Supplier: Accord Barnstaple 3. 3. Revised By: M.Doak 4. Pharmacode: 5778 5. Proof Round Date Sent: 26/10/20 Technical Date sent: N/A 6. Approval Date received: N/A Technologist: T. Hull 2 Technically Approved [email protected] Cartons and label leaflets only (labels only when specified) German GTIN 14 (incorporating PZN): N/A * Please note that only Artwork Studio is permitted to make changes to the above artwork. Version 7 No changes are permitted by any 3rd party other than added notes and mark ups for required changes. 12.02.2020 Surgery Verapamil tablets and alcohol Elderly with heart or liver problems: you may be given Tell your doctor if you notice any of the following side You should tell your doctor you are taking Verapamil Verapamil may increase the amount of alcohol in the a different dose. effects, they get worse or you notice any other effects tablets if you are having an operation or anaesthetic. body and the time it takes for alcohol to leave the body. not listed: Use in children and adolescents Nervous system – headaches, dizziness, ‘pins and Other medicines and Verapamil tablets You should avoid excessive amounts of alcohol whilst • Up to 2 years: 20mg two or three times a day. needles’, involuntary shaking or spasm Tell your doctor or pharmacist if you are taking, have taking Verapamil tablets. • 2 years and over: 40-120mg two or three times a day. Ears – spinning sensation, ‘ringing in the ears’ recently taken or might take any other medicines, Heart /blood vessels – fast, slow or irregular heartbeat, especially: Verapamil tablets and Grapefruit juice Swallow the tablets whole with water, without chewing low blood pressure, flushing/reddening of the skin, • ivabradine (for heart disease) Do not eat or drink products containing grapefruit juice or crushing them. swelling of the ankles, hands or feet • alpha or beta blockers (particularly important if having whilst taking verapamil, as grapefruit juice increases the Stomach – constipation, feeling or being sick, pain or a beta blocker by injection) and other drugs to treat effects of verapamil. If you take more Verapamil tablets than you should discomfort in the stomach, swelling of the gums high blood pressure e.g. prazosin If you (or someone else) swallow a lot of tablets at the Skin – hair loss, skin rash or itching, discolouring, burning • cimetidine (to treat stomach ulcers) Pregnancy and breast-feeding same time, or you think a child may have swallowed any, pain associated with increased skin temperature • phenobarbital, carbamazepine or phenytoin (to treat If you are pregnant or breast-feeding, think you may be contact your nearest hospital casualty department or tell Muscles – muscle weakness, tremor, aches and pains in epilepsy) pregnant or are planning to have a baby, ask your doctor your doctor immediately. Overdose can lead to low blood the joints and/or muscles • rifampicin, erythromycin, clarithromycin or or pharmacist for advice before taking this medicine. pressure and in rare cases heart failure. Reproductive system – erectile dysfunction, enlarged telithromycin (to treat infections) breasts in men (reversible when treatment is stopped), • ritonavir (to treat HIV) Driving and using machines If you forget to take Verapamil tablets milky secretion from the breasts • lithium (to treat depression) Verapamil tablets may make you feel drowsy, particularly Do not take a double dose to make up for a forgotten Other – tiredness, liver problems which can be indicated • theophylline (to treat asthma) when you first start the treatment and when changing dose. If you forget to take a dose, take it as soon as you by yellowing of the skin or eyes and detected by blood • digoxin (to treat certain heart conditions) over from another medicine. Make sure you are not remember. If it is nearly time for the next dose, skip the tests done by your doctor. • midazolam (used as sedative or anaesthetic) affected before you drive or operate machinery, missed dose and take the next dose at the right time. • statins e.g. simvastatin, atorvastatin (to lower especially if taken with alcohol. Reporting of side effects cholesterol levels) If you stop taking Verapamil tablets If you get any side effects, talk to your doctor, pharmacist • imipramine (to treat depression, anxiety and panic Verapamil tablets contain sunset yellow aluminium Talk to your doctor before you stop taking the tablets or nurse. This includes any possible side effects not listed disorder) lake (E110) and follow their advice. in this leaflet. You can also report side effects directly via • aspirin (for pain, fever or to prevent blood clots) Sunset yellow aluminium lake (E110) may cause allergic If you stop taking your tablets your condition may get the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard • almotriptan (to treat migraine) reactions. worse. It is important that you keep taking these tablets or search for MHRA Yellow Card in Google Play or Apple • dabigatran (medicine to prevent the formation of blood until your doctor tells you to stop, do not stop because App Store. clots) 3 How to take Verapamil tablets you feel better. • quinidine or flecainide (to treat arrhythmias) Always take this medicine exactly as your doctor has told By reporting side effects you can help provide more • colchicine or sulfinpyrazone (for gout) you. Check with your doctor or pharmacist if you are not If you have any further questions on the use of this information on the safety of this medicine. • glibenclamide (to treat certain types of diabetes) sure. medicine, ask your doctor or pharmacist.
Recommended publications
  • A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015 S

    A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015 S

    Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2016/11/07/dmd.116.073411.DC1 1521-009X/45/1/86–108$25.00 http://dx.doi.org/10.1124/dmd.116.073411 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 45:86–108, January 2017 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Minireview What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015 s Jingjing Yu, Zhu Zhou,1 Katie H. Owens, Tasha K. Ritchie, and Isabelle Ragueneau-Majlessi Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington Received September 1, 2016; accepted November 2, 2016 Downloaded from ABSTRACT As a follow up to previous reviews, the aim of the present analysis substrates of CYP3A (AUC ratio ‡ 5 when coadministered with was to systematically examine all drug metabolism, transport, strong inhibitors): cobimetinib, isavuconazole (the active metabolite pharmacokinetics (PK), and drug-drug interaction (DDI) data avail- of prodrug isavuconazonium sulfate), and ivabradine. As perpetra- able in the 33 new drug applications (NDAs) approved by the Food tors, nine NMEs showed positive inhibition and three NMEs showed and Drug Administration (FDA) in 2015, using the University of positive induction, with some of these interactions involving both dmd.aspetjournals.org Washington Drug Interaction Database, and to highlight the signif- enzymes and transporters. The most significant changes for in- icant findings. In vitro, a majority of the new molecular entities hibition and induction were observed with rolapitant, a moderate (NMEs) were found to be substrates or inhibitors/inducers of at least inhibitor of CYP2D6 and lumacaftor, a strong inducer of CYP3A.
  • Procoralan, INN-Ivabradine

    Procoralan, INN-Ivabradine

    SCIENTIFIC DISCUSSION List of abbreviations AE Adverse event AF Atrial fibrillation 95% CI 95% confidence interval ALAT Alanine aminotransferase ALP Alkaline phosphatase ALT Alanine transaminase, alanine aminotransferase ASAT Aspartate aminotransferase AST Aspartate aminotransferase AUC Area under the curve AWth Thickening of the anterior wall b.i.d. Twice daily blq Below limit of quantification bpm Beats per minute BSE Bovine Spongiform Encephalopathy CABG Coronary artery bypass graft CAD Coronary artery disease CCS Canadian cardiovascular society CHMP Committee of Medicinal Products for Human Use CL Total clearance Cmax Maximum plasma concentration CNS Central nervous system COPD Chronic Obstructive Pulmonary Disease CPK Creatine phospho kinase CYP3A4 Cytochrome P450 isoenzyme 3A4 DBP Diastolic blood pressure DT Diastolic time e.g. exempla gratia (for example) EAE Emergent adverse event ECG Electrocardiogram EMEA European Medicines Agency ERG Electroretinography ETT Exercise tolerance tests F Absolute bioavailability FAS Full Analysis Set FDA Food and Drug Administration GC Gas Chromatography GGT Gammaglutamyltranspeptidase GLP Good laboratory practice HbA1c Glycosylated haemoglobin HCN Hyperpolarisation-activated cyclic-nucleotide-gated channel HCV Hepatitis C virus HF Heart failure HIV Human immunodeficiency virus HPLC High-performance liquid chromatography HR Heart rate HRR Heart rate reduction International conference on harmonisation of technical requirements for ICH registration of pharmaceuticals for human use i.e. id est i.v.
  • Cocaine Intoxication and Hypertension

    Cocaine Intoxication and Hypertension

    THE EMCREG-INTERNATIONAL CONSENSUS PANEL RECOMMENDATIONS Cocaine Intoxication and Hypertension Judd E. Hollander, MD From the Department of Emergency Medicine, University of Pennsylvania, Philadelphia, PA. 0196-0644/$-see front matter Copyright © 2008 by the American College of Emergency Physicians. doi:10.1016/j.annemergmed.2007.11.008 [Ann Emerg Med. 2008;51:S18-S20.] with cocaine intoxication is analogous to that of the patient with hypertension: the treatment should be geared toward the Cocaine toxicity has been reported in virtually all organ patient’s presenting complaint. systems. Many of the adverse effects of cocaine are similar to When the medical history is clear and symptoms are mild, adverse events that can result from either acute hypertensive laboratory evaluation is usually unnecessary. In contrast, if the crisis or chronic effects of hypertension. Recognizing when the patient has severe toxicity, evaluation should be geared toward specific disease requires treatment separate from cocaine toxicity the presenting complaint. Laboratory evaluation may include a is paramount to the treatment of patients with cocaine CBC count; determination of electrolyte, glucose, blood urea intoxication. nitrogen, creatine kinase, and creatinine levels; arterial blood The initial physiologic effect of cocaine on the cardiovascular gas analysis; urinalysis; and cardiac marker determinations. system is a transient bradycardia as a result of stimulation of the Increased creatine kinase level occurs with rhabdomyolysis. vagal nuclei. Tachycardia typically ensues, predominantly from Cardiac markers are increased in myocardial infarction. Cardiac increased central sympathetic stimulation. Cocaine has a troponin I is preferred to identify acute myocardial13 infarction. cardiostimulatory effect through sensitization to epinephrine A chest radiograph should be obtained in patients with and norepinephrine.
  • Australian Pi – Coralan (Ivabradine As the Hydrochloride)

    Australian Pi – Coralan (Ivabradine As the Hydrochloride)

    Australian Product Information – CORALAN (ivabradine as the hydrochloride) AUSTRALIAN PI – CORALAN (IVABRADINE AS THE HYDROCHLORIDE) 1 NAME OF THE MEDICINE Ivabradine (as the hydrochloride) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each CORALAN 5 mg film-coated tablet contains 5 mg of ivabradine (as the hydrochloride) Each CORALAN 7.5 mg film-coated tablet contains 7.5 mg of ivabradine (as the hydrochloride) The active component of CORALAN is ivabradine which has the chemical name (3-(3-{[((7S)-3,4- Dimethoxybicyclo[4,2,0]octa-1,3,5-trien-7-yl) methyl] methylamino}propyl)-1,3,4,5-tetrahydro-7,8- dimethoxy-2H-3-benzazepin-2-one, hydrochloride). It contains two rings: one benzazepinone and one benzocyclobutane linked with an azapentane chain. The structural form of ivabradine includes one asymmetric carbon and ivabradine corresponds to the S enantiomer. The hydrochloride salt is a white hygroscopic powder, soluble in water (50 mg/mL) and in 0.9% saline solution (14 mg/mL). The pH is 5.1 - 5.4 in aqueous solutions at concentration of 10 mg/mL Excipients with known effect: Each CORALAN 5 mg tablet contains 63.91 mg of lactose. Each CORALAN 7.5 mg tablet contains 61.215 mg of lactose. For the full list of excipients, see section 6.1 - List of excipients 3 PHARMACEUTICAL FORM CORALAN 5 mg: salmon-pink coloured, rod-shaped, film-coated tablet scored on both edges, engraved with “5” on one face and the company logo “ ” on the other. CORALAN 7.5 mg: salmon-pink coloured, triangular, film-coated tablet engraved with “7.5” on one face and the company logo “ ”on the other.
  • “Contraindication” Versus “Avoid Concomitant Use” by JOHN R

    “Contraindication” Versus “Avoid Concomitant Use” by JOHN R

    RX FOCUS Drug Interactions “Contraindication” Versus “Avoid Concomitant Use” BY JOHN R. HORN, PHARMD, FCCP, AND PHILIP D. HANSTEN, PHARMD IN THE OFFICIAL PRESCRIBING INFORMATION OF inducers in this category; data show a 62% decrease PHARMACEUTICAL PRODUCTS, drug interactions are in the ivabradine AUC with the use of St. John’s wort often listed in 2 categories: “contraindicated” and and an 80% decrease with the use of carbamazepine.4,5 “avoid concomitant use.” Is this a distinction without a difference? The Medline Plus definition of “contra- PRACTICAL CONSIDERATIONS indication” is “…a specific situation in which a drug, With regard to ivabradine drug interactions, is there procedure, or surgery should not be used because it may a practical difference between the designations of be harmful to the person.” Other official definitions “contraindicated” and “avoid concomitant use?” First, JOHN R. HORN, PHARMD, FCCP are similar to this, which raises the question, how is regarding CYP3A4 inducers, it could be argued that this different from “avoid concomitant use?” Let us they should never be given with ivabradine because iv- explore this issue using, as an example, ivabradine abradine plasma concentrations would almost always (Corlanor), a drug used to treat heart failure. be subtherapeutic. Thus, it would seem that CYP3A4 in- ducers might be best listed as “contraindicated” rather INTERACTIVE PROPERTIES OF than under “avoid concurrent use.” IVABRADINE Regarding “strong” CYP3A4 inhibitors, given that Ivabradine is primarily metabolized by CYP3A4 in ivabradine has potentially serious dose-dependent PHILIP D. HANSTEN, PHARMD the gut and liver, and its bioavailability is only about adverse cardiovascular effects, it seems reasonable 40% due to first-pass metabolism.
  • SASH-IVABRADINE-Heart-Failure

    SASH-IVABRADINE-Heart-Failure

    WORKING IN PARTNERSHIP WITH Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath) North East Hampshire & Farnham CCG and Crawley, Horsham & Mid-Sussex CCG Information sheet IVABRADINE Treatment in selected patients with chronic, stable heart failure (NYHA II – IV) The Prescribing Clinical Network recommends Ivabradine in line with NICE guidance (TA267 November 2012). Ivabradine should be initiated under the supervision of a cardiologist. Prescribing Clinical Network classification: Amber* Amber*: Drugs that require initiation by a specialist in secondary / tertiary care but due to more widespread experience in primary care GPs are generally happy to prescribe on specialist advice without the need for a formal shared care protocol. This information sheet is available on the internet (www.surreyhealth.nhs.uk) forming part of Prescribing Advisory Database (PAD) giving GPs appropriate advice / guidance and is not required to be sent to the GP with the clinic letter. A minimum of one month supply of medication will be provided by the initiating consultant. RESPONSIBILITIES and ROLES Specialist responsibilities 1. Assess the patient to determine suitability for prescribing of ivabradine; ensuring other treatment options have been fully explored. 2. The treatment to be initiated in patients with stable heart failure. Initiate treatment with Ivabradine (initial 1 month supply from Acute Trust Pharmacy). 3. Carry out ECG to monitor the patient for signs of atrial fibrillation if clinically indicated, 4. Provision of advice to patient and GP on further management of treatment for optimum control of symptoms and related issues such as drug interactions. 5. The patient, once stable after 6 months, will be discharged back to the GP with a management plan.
  • Anaesthetic Implications of Calcium Channel Blockers

    Anaesthetic Implications of Calcium Channel Blockers

    436 Anaesthetic implications of calcium channel Leonard C. Jenkins aA MD CM FRCPC blockers Peter J. Scoates a sc MD FRCPC CONTENTS The object of this review is to emphasize the anaesthetic implications of calcium channel block- Physiology - calcium/calcium channel blockers Uses of calcium channel blockers ers for the practising anaesthetist. These drugs have Traditional played an expanding role in therapeutics since their Angina pectoris introduction and thus anaesthetists can expect to see Arrhythmias increasing numbers of patients presenting for anaes- Hypertension thesia who are being treated with calcium channel Newer and investigational Cardiac blockers. Other reviews have emphasized the basic - Hypertrophic cardiomyopathy pharmacology of calcium channel blockers. 1-7 - Cold cardioplegia - Pulmonary hypertension Physiology - calcium/calcium channel blockers Actions on platelets Calcium plays an important role in many physio- Asthma Obstetrics logical processes, such as blood coagulation, en- - Premature labor zyme systems, muscle contraction, bone metabo- - Pre-eclampsia lism, synaptic transmission, and cell membrane Achalasia and oesophageal spasm excitability. Especially important is the role of Increased intraocular pressure therapy calcium in myocardial contractility and conduction Protective effect on kidney after radiocontrast Cerebral vasospasm as well as in vascular smooth muscle reactivity. 7 Induced hypotensive anaesthesia Thus, it can be anticipated that any drug interfering Drag interactions with calcium channel blockers with the action of calcium could have widespread With anaesthetic agents effects. Inhalation agents In order to understand the importance of calcium - Effect on haemodynamics - Effect on MAC in cellular excitation, it is necessary to review some Neuromuscular blockers membrane physiology. Cell membranes are pri- Effects on epinephrine-induced arrhythmias marily phospholipids arranged in a bilayer.
  • ISOPTIN® 1. Product Name 2. Qualitative and Quantitative

    ISOPTIN® 1. Product Name 2. Qualitative and Quantitative

    NEW ZEALAND DATA SHEET ISOPTIN® 1. Product Name Isoptin, 5 mg/2 mL, solution for injection. 2. Qualitative and Quantitative Composition Each ampoule contains 2.5 mg/mL verapamil hydrochloride (equivalent to 2.3 mg/mL verapamil) and sodium chloride 8.5 mg/mL in water for injection. For the full list of excipients, see section 6.1. 3. Pharmaceutical Form Verapamil hydrochloride injection is a sterile, nonpyrogenic solution that contains no bacteriostatic or antimicrobial agent and is intended for single-dose intravenous administration. It may contain hydrochloric acid for pH adjustment; pH is 4.9 (4.0 to 6.5). 4. Clinical Particulars 4.1 Therapeutic indications Tachycardias, such as paroxysmal supraventricular tachycardia, atrial fibrillation with rapid ventricular response, (except in WPW syndrome, see section 4.4), atrial flutter with rapid conduction, extrasystoles. For the prophylaxis and/or therapy of ectopic arrhythmias (predominantly ventricular extrasystoles) in halothane anaesthesia and in the application of adrenaline in halothane anaesthesia, respectively. Acute hypertension. Acute coronary insufficiency. 4.2 Dose and method of administration Dose Adults 5 mg slowly intravenously, in tachycardias and hypertensive crises repeated, if necessary, after 5 to 10 minutes. Drip infusion to maintain the therapeutic effect: 5-10 mg/hour in physiological saline, glucose, laevulose or similar solutions, on average up to a total dose of 100 mg/day. Special populations Paediatric Newborn 0.75-1 mg (= 0.3-0.4 mL) Infants 0.75-2 mg (= 0.3-0.8 mL) Page 1 of 12 Children (aged 1-5 years) 2-3mg (= 0.8-1.2 mL) (aged 6-14 years) 2.5-5mg (= 1-2 mL) of Isoptin, given intravenously, depending on age and action.
  • Verapamil Inhibits TRESK (K2P18.1) Current in Trigeminal Ganglion Neurons Independently of the Blockade of Ca2+ Influx

    Verapamil Inhibits TRESK (K2P18.1) Current in Trigeminal Ganglion Neurons Independently of the Blockade of Ca2+ Influx

    International Journal of Molecular Sciences Article Verapamil Inhibits TRESK (K2P18.1) Current in Trigeminal Ganglion Neurons Independently of the Blockade of Ca2+ Influx Hyun Park 1, Eun-Jin Kim 2, Ji Hyeon Ryu 2,3, Dong Kun Lee 2,3, Seong-Geun Hong 2,3, Jaehee Han 2, Jongwoo Han 1,* and Dawon Kang 2,3,* ID 1 Department of Neurosurgery, College of Medicine and Institute of Health Sciences, Gyeongsang National University, Jinju 52727, South Korea; [email protected] 2 Department of Physiology and Institute of Health Sciences, College of Medicine, Gyeongsang National University, Jinju 52727, South Korea; [email protected] (E.-J.K.); [email protected] (J.H.R.); [email protected] (D.K.L.); [email protected] (S.-G.H.); [email protected] (J.H.) 3 Department of Convergence Medical Science, Gyeongsang National University, Jinju 52727, South Korea * Correspondence: [email protected] (J.H.); [email protected] (D.K.); Tel.: +82-55-772-8044 (D.K.) Received: 5 June 2018; Accepted: 2 July 2018; Published: 4 July 2018 Abstract: Tandem pore domain weak inward rectifier potassium channel (TWIK)-related spinal cord + + K (TRESK; K2P18.1) channel is the only member of the two-pore domain K (K2P) channel family 2+ 2+ that is activated by an increase in intracellular Ca concentration ([Ca ]i) and linked to migraines. This study was performed to identify the effect of verapamil, which is an L-type Ca2+ channel blocker and a prophylaxis for migraines, on the TRESK channel in trigeminal ganglion (TG) neurons, as well as in a heterologous system.
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1

    Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1

    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
  • Calcium Channel Blockers

    Calcium Channel Blockers

    Calcium Channel Blockers Summary In general, calcium channel blockers (CCBs) are used most often for the management of hypertension and angina. There are 2 classes of CCBs: the dihydropyridines (DHPs), which have greater selectivity for vascular smooth muscle cells than for cardiac myocytes, and the non-DHPs, which have greater selectivity for cardiac myocytes and are used for cardiac arrhythmias. The DHPs cause peripheral edema, headaches, and postural hypotension most commonly, all of which are due to the peripheral vasodilatory effects of the drugs in this class of CCBs. The non-DHPs are negative inotropes and chronotropes; they can cause bradycardia and depress AV node conduction, increasing the risk of heart failure exacerbation, bradycardia, and AV block. Clevidipine is a DHP calcium channel blocker administered via continuous IV infusion and used for rapid blood pressure reductions. All CCBs are substrates of CYP3A4, but both diltiazem and verapamil are also inhibitors of 3A4 and have an increased risk of drug interactions. Verapamil also inhibits CYP2C9, CYP2C19, and CYP1A2. Pharmacology CCBs selectively inhibit the voltage-gated L-type calcium channels on cardiac myocytes, vascular smooth muscle cells, and cells within the sinoatrial (SA) and atrioventricular (AV) nodes, preventing influx of extracellular calcium. CCBs act by either deforming the channels, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the major cellular calcium store, the endoplasmic reticulum. Calcium influx via these channels serves for excitation-contraction coupling and electrical discharge in the heart and vasculature. A decrease in intracellular calcium will result in inhibition of the contractile process of the myocardial smooth muscle cells, resulting in dilation of the coronary and peripheral arterial vasculature.
  • Corlanor® (Ivabradine) Clinical Fact Sheet

    Corlanor® (Ivabradine) Clinical Fact Sheet

    Corlanor® (ivabradine) Clinical Fact Sheet Corlanor® FDA-Approved Indications1 • Corlanor® is indicated to reduce the risk of hospitalization for Figure 1: Etiology of HF5 worsening heart failure in adult patients with stable, Enlarged Chambers Enlarged Chambers symptomatic chronic heart failure with left ventricular ejection • The chambers of the heart stretch and fraction ≤ 35%, who are in sinus rhythm with resting heart contract more strongly, increasing blood flow rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to Increased Muscle Mass beta-blocker use. • The increase in muscle mass occurs when the contracting cells of the heart expand, allowing • Corlanor® is indicated for the treatment of stable symptomatic the heart to pump more strongly (at least initially) heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm Neurendocrine Axis and Sympathetic Tone with an elevated heart rate. • Perfusion, contractility, and heart rate all increase Heart Failure (HF) In HF, the body Ventricular Cardiac Heart Cardiac blood filling muscle • According to 2013–2016 NHANES data, approximately 6.2 compensates rate volume pressure million people ≥ 20 years old in the US have HF2 to increase:5 mass • The lifetime risk of developing HF is 20% to 45% for adults at As HF progresses, reduced ejection fraction results in reduced cardiac 45 through 95 years of age2 output and increased end systolic and diastolic volume. With less fluid • HF is the leading cause of rehospitalization in adult patients moving out of the heart, pulmonary congestion worsens.